Who are isoniazid and rifapentine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): isoniazid , randomized, open label.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isoniazid-and-rifapentine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

isoniazid and rifapentine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

isoniazid and rifapentine (isoniazid and rifapentine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antitubercular agent. Area: Infectious disease.

phase 3 Antitubercular agent InhA (enoyl-acyl carrier protein reductase), RNA polymerase Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

isoniazid and rifapentine (isoniazid and rifapentine) — National Taiwan University Hospital. Isoniazid and rifapentine work by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis, ultimately leading to the death of the bacteria.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
isoniazid and rifapentine TARGET	isoniazid and rifapentine	National Taiwan University Hospital	phase 3	Antitubercular agent	InhA (enoyl-acyl carrier protein reductase), RNA polymerase
isoniazid , randomized, open label	isoniazid , randomized, open label	National Taiwan University Hospital	phase 3	Antitubercular agent	InhA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antitubercular agent class)

National Taiwan University Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). isoniazid and rifapentine — Competitive Intelligence Brief. https://druglandscape.com/ci/isoniazid-and-rifapentine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab